State Street SPDR S&P Biotech ETF
193 hedge funds and large institutions have $3.95B invested in State Street SPDR S&P Biotech ETF in 2015 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 52 increasing their positions, 68 reducing their positions, and 20 closing their positions.
70% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 20
65.46% more ownership
Funds ownership: 389.07% → 454.52% (+65%)
43% more capital invested
Capital invested by funds: $2.76B → $3.95B (+$1.19B)
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
7% more funds holding
Funds holding: 180 → 193 (+13)
24% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 68
67% less call options, than puts
Call options by funds: $689M | Put options by funds: $2.06B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$176M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$175M |
| 3 |
Morgan Stanley
New York
|
+$125M |
| 4 |
Citigroup
New York
|
+$69.5M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$49.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$13.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$11.1M |
| 3 |
Jane Street
New York
|
-$5.01M |
| 4 |
LRPA
L. Roy Papp & Associates
Phoenix,
Arizona
|
-$3.65M |
| 5 |
VCAM
Valentine Capital Asset Management
Danville,
California
|
-$2.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MC
201
Moors & Cabot
Boston,
Massachusetts
| – | -$655K | -8,715 | Closed |
|
202
Franklin Resources
San Mateo,
California
| – | -$631K | -8,400 | Closed |
|
|
MSU
203
Maple Securities USA
Jersey City,
New Jersey
| – | -$495K | -6,579 | Closed |
|
|
CC
204
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
| – | -$474K | -6,300 | Closed |
|
|
PCM
205
Prelude Capital Management
New York
| – | -$474K | -6,300 | Closed |
|
|
WS
206
Wedbush Securities
Los Angeles,
California
| – | -$361K | -4,803 | Closed |
|
|
TRCT
207
Tower Research Capital (TRC)
New York
| – | -$278K | -3,702 | Closed |
|
|
BAS
208
Brown Advisory Securities
Baltimore,
Maryland
| – | -$247K | -3,294 | Closed |
|
|
PPA
209
Parametric Portfolio Associates
Seattle,
Washington
| – | -$206K | -2,742 | Closed |
|
|
SHJ
210
Sharkey, Howes & Javer
Denver,
Colorado
| – | -$158K | -2,100 | Closed |
|
|
PSI
211
Pinnacle Summer Investments
Fairfax,
Virginia
| – | -$24K | -318 | Closed |
|
|
MC
212
Maplelane Capital
New York
| – | +$233 | +3 | New |
|
XBI Hedge Fund Activity: Q2 2015 in Review
193 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2015, worth a combined $3.95B — up 43% from $2.76B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new XBI positions and 20 closed out — a net gain of 14 holders — while 52 added to existing stakes and 68 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $176M. The largest seller was State of Wisconsin Investment Board, cutting an estimated $13.5M.
- 193 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2015, up from 180 in Q1 2015.
- Funds reported $3.95B of State Street SPDR S&P Biotech ETF stock for Q2 2015, up 43% quarter-over-quarter.
- 34 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2015 and 20 closed out, a net change of +14 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2015 was Goldman Sachs, an estimated $176M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2015 was State of Wisconsin Investment Board, an estimated $13.5M sold.
Based on aggregated 13F filings for Q2 2015.